Potential Effects on Elderly People From Nirsevimab Use in Infants

• 2024

  Log in to bookmark this resource.

  Log in
• Iván Sanz-Muñoz; Javier Castrodeza-Sanz; José Eiros
PMID: 38617129DOI: https://doi.org/10.1016/j.opresp.2024.100320

---

Access Resources

• Journal ArticleEN
• Ask aRCie About This Resource

About

This article is about nirsevimab, a new treatment for infants to prevent severe RSV disease. It describes how using nirsevimab in babies might help protect elderly people by reducing the virus's spread. However, the effect on older adults may be small because they often catch RSV from school-aged children or other seniors. The article suggests that while nirsevimab could lower viral load in infants, it won't significantly stop its spread to the elderly. Therefore, vaccines specifically for older adults should be prioritized to protect them from RSV effectively.

---

Tags

Focus Area: Infectious Disease

Keywords: Aged; Infant, Newborn; Respiratory Syncytial Virus Infections; Vaccines; Respiratory Syncytial Virus, Human

Emergency Management Stage: Preparedness (Prevention / Protection)

Audience: Physicians

Format: Journal Article

Media Type: Website

Institutions: World Health Organization (WHO); Instituto de Estudios de Ciencias de la Salud de Castilla y León, ICSCYL; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFECC); University of Valladolid

Institution Types: International Government; Non-Governmental Organization; Academic; Non-Governmental Organization

Language: English

Bundles: Nirsevimab Library

---

More like this

Potential Effects on Elderly People From Nirsevimab Use in Infants 2024 · World Health Organization (WHO), Instituto de Estudios de Ciencias de la Salud de Castilla y León, ICSCYL, Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFECC), University of Valladolid Assessment of Effectiveness and Impact of Universal Prophylaxis With Nirsevimab for Prevention of Hospitalizations Due to Respiratory Syncytial Virus in Infants. The NIRSE-GAL Study Protocol 2024 · Instituto de Investigación Sanitaria, World Health Organization (WHO), University of Santiago de Compostela, Instituto de Salud Carlos III Equitable Access to RSV Prevention: Challenges and Opportunities With Nirsevimab's Rollout 2024 · George Washington University, Children's National Hospital

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---